We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Download Mobile App




Tiny Molecule Found to Boost Production of Brain Cells, Protects New Cells from Dying

By LabMedica International staff writers
Posted on 11 Aug 2010
Researchers have found a compound that preserves newly created brain cells and boosts learning and memory in an animal study.

The study of this compound, which appears in the July 9, 2010, issue of the journal Cell, springs from a US$2.5 million National Institutes of Health (NIH; Bethesda, MD, USA) Director's Pioneer Award to Dr. More...
Steven McKnight, chairman of biochemistry at University of Texas (UT) Southwestern Medical Center (Dallas, USA) and senior author of the study. Over a three-year period, the research team led by Dr. McKnight and Dr. Andrew Pieper, assistant professor of psychiatry and biochemistry at UT Southwestern, screened 1,000 individual molecules to see which ones might enhance the production of neurons in the adult mouse hippocampus, a region of the brain critical to learning and memory. The scientists found that one of the compounds, called P7C3, achieved this by protecting newborn neurons from dying.

The researchers then administered P7C3 to "knockout” mice lacking a gene that controls the generation of new neurons in the hippocampus. Humans who lack this gene have a variety of learning disabilities, and the knockout rodents show related abnormalities as well as a poorly formed hippocampus. When the knockout mouse received P7C3, however, normal structure and function of the hippocampus were restored.

In elderly rats, which characteristically show a decline in the birth and formation of hippocampal neurons, the researchers discovered that P7C3 increased both the birth and survival of new neurons, and the memory and learning capability of the aged rats. "It's been a wonderful experience,” Dr. Pieper said. "At first there was a lot of doubt, because we could have gone through the whole screen and found nothing.”

The researchers are now evaluating the process by which P7C3 protects cells from dying, and whether it might have any protective effect in other models of neurodegenerative disease. "We don't know yet whether P7C3 can block the death of mature nerve cells, which is what occurs in humans with these conditions,” Dr. McKnight said.

Dr. McKnight was one of the first 12 recipients of the NIH Director's Pioneer Award, which is designed to allow researchers to pursue risky experiments that have the potential for producing highly innovative results. "When I received the award, I thought ‘I'm not going to waste it on something safe--I'm going to go for it. That's what the NIH expected of me and my team,'” Dr. McKnight said. "I'd like to give the NIH credit for betting on ‘cowboy' science. If this pans out, it will be the most useful contribution of my career."

Dr. Francis Collins, director of the NIH, said Dr. McKnight's results precisely fit the award's purpose. "The NIH Director's Pioneer Award gives highly innovative investigators the freedom to pursue bold new avenues of research. Such approaches can yield substantial payoffs, as in the case of the exciting clinical implications of Prof. McKnight's basic neurobiological research discovery,” Dr. Collins said.

Related Links:
University of Texas Southwestern Medical Center



Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Verification Panels for Assay Development & QC
Seroconversion Panels
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Rheumatoid Factors (RF) Test
Rheumatoid Factors (RF)
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.